ArticleHaematologica2018
GFI1 is required for
Abstract readLetter
In one paragraph
Article in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- CoREST in pieces: Dismantling the CoREST complex for cancer therapy and beyond.Science advances · 2025Review
- Germline Single-Nucleotide PolymorphismBiomedicines · 2025Article
- Dysregulated innate immune signaling cooperates with RUNX1 mutations to transform an MDS-like disease to AML.iScience · 2024Article
- Understanding blood development and leukemia using sequencing-based technologies and human cell systems.Frontiers in molecular biosciences · 2023Review
- Article
- Epigenetic Crosstalk between Malignant Plasma Cells and the Tumour Microenvironment in Multiple Myeloma.Cancers · 2022Review
- GFI1-Dependent Repression ofCancers · 2022Article
- AML1/ETO and its function as a regulator of gene transcription via epigenetic mechanisms.Oncogene · 2021Review
- A PML/RARα direct target atlas redefines transcriptional deregulation in acute promyelocytic leukemia.Blood · 2021Article
- Multifaceted Actions of GFI1 and GFI1B in Hematopoietic Stem Cell Self-Renewal and Lineage Commitment.Frontiers in genetics · 2020Review
- Epigenetic-Based Mechanisms of Osteoblast Suppression in Multiple Myeloma Bone Disease.JBMR plus · 2019Review
- Targeting the GFI1/1B-CoREST Complex in Acute Myeloid Leukemia.Frontiers in oncology · 2019Review
- Role of GFI1 in Epigenetic Regulation of MDS and AML Pathogenesis: Mechanisms and Therapeutic Implications.Frontiers in oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Anna E MarnethDepartment of Laboratory Medicine, Laboratory of Hematology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands.
Lacramioara BotezatuDepartment of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Germany.
Judith M HönesDepartment of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Germany.
Jimmy C L IsraëlDepartment of Laboratory Medicine, Laboratory of Hematology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands.
Judith SchütteDepartment of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Germany.
Lothar VassenDepartment of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Germany.
Robert F LamsDepartment of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Germany.
Saskia M BergevoetDepartment of Laboratory Medicine, Laboratory of Hematology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands.
Laura GroothuisDepartment of Laboratory Medicine, Laboratory of Hematology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands.
Amit MandoliDepartment of Molecular Biology, Faculty of Science, Radboud Institute for Molecular Life Sciences, Radboud University Nijmegen, The Netherlands.
Joost H A MartensDepartment of Molecular Biology, Faculty of Science, Radboud Institute for Molecular Life Sciences, Radboud University Nijmegen, The Netherlands.
Gerwin HulsDepartment of Hematology, University Medical Center Groningen, University of Groningen, The Netherlands.
Joop H JansenDepartment of Laboratory Medicine, Laboratory of Hematology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands.
Ulrich DührsenDepartment of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Germany.
Tobias BergDepartment of Medicine II-Hematology/Oncology, Goethe University, Frankfurt/Main, Germany.
Tarik MöröyInstitut de recherches cliniques de Montréal (IRCM), Hematopoiesis and Cancer Research Unit, and Université de Montréal, Canada.
Christian WichmannDepartment of Transfusion Medicine, Cell Therapeutics and Hemostaseology, Ludwig-Maximilian University Hospital, Munich, Germany.
Mia-Chia LoDepartment of Pathology & Division of Biological Sciences, University of California San Diego, La Jolla, USA.
Dong-Er ZhangDepartment of Pathology & Division of Biological Sciences, University of California San Diego, La Jolla, USA.
Bert A van der ReijdenDepartment of Laboratory Medicine, Laboratory of Hematology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands Cyrus.Khandanpour@uk-essen.de Cyrus.Khandanpour@ukmuenster.de Bert.vanderReijden@radboudumc.nl.
Cyrus KhandanpourDepartment of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Germany Cyrus.Khandanpour@uk-essen.de Cyrus.Khandanpour@ukmuenster.de Bert.vanderReijden@radboudumc.nl.
Funding
Molecular Mechanism of Leukemogenesis Involving AML1-ETOR01CA104509 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZHANG, DONG-ER · 2004 to 2025
$6.6MCIHRNCI NIH HHS R01 CA104509
Abstract
PubMed holds no abstract for this paper.
Indexed as
Biomarkers, TumorCell Transformation, NeoplasticDisease ProgressionDNA-Binding ProteinsGene Expression Regulation, LeukemicHumansLeukemia, Myeloid, AcuteOncogene Proteins, FusionPrognosisRUNX1 Translocation Partner 1 ProteinTranscription FactorsBiomarkers, TumorDNA-Binding ProteinsGFI1 protein, humanOncogene Proteins, FusionRUNX1 Translocation Partner 1 ProteinTranscription Factors
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.